The Technical Analyst
Select Language :

Ocuphire Pharma, Inc. [OCUP]

Exchange: Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Ocuphire Pharma, Inc. is listed at the NASDAQ Exchange

5.20% $4.35

Last updated: 28 Nov 2021 @ 18:31 pm


FUNDAMENTALS
MarketCap: 75.26 mill
EPS: -5.62
P/E: 0.000
Earnings Date: Nov 12, 2021
SharesOutstanding: 17.30 mill
Avg Daily Volume: 1.706 mill
RATING 2021-11-26
B
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/204/201/212/213/21
Revenuen/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset n/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
nanx
Company: PE 0.000 | sector: PE nan
PE RATIO: COMPANY / INDUSTRY
nanx
Company: PE 0.000 | industry: PE nan
DISCOUNTED CASH FLOW VALUE
$8.76
(101.45%) $4.41
Date: 2021-11-28

Insider Trading

Date Person Action Amount type
2021-11-18 Manuso James S J Buy 2 000 Common Stock
2021-10-01 Benton Susan Buy 2 135 Common Stock
2021-10-01 Rodgers Richard J Buy 2 912 Common Stock
2021-09-13 Pepose Jay Buy 12 631 Common Stock
2021-09-02 Benton Susan Buy 20 000 Common Stock
INSIDER POWER
98.67
Last 92 transactions
Buy: 4 406 398 | Sell: 1 625

Forecast: 16:00 - $4.26

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $4.26
Forecast 2: 16:00 - $4.26
Forecast 3: 16:00 - $4.26
SCORE
0.38
Hold
Score Algorithm Version: 0.9M
Last version updated: Thurs 28th Oct 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $4.35 (5.20% )
Volume 6.58 mill
Avg. Vol. 1.706 mill
% of Avg. Vol 385.94 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Ocuphire Pharma, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Ocuphire Pharma, Inc.

RSI

Intraday RSI14 chart for Ocuphire Pharma, Inc.
The Live Chart for Ocuphire Pharma, Inc.
Profile picture for
            Ocuphire Pharma, Inc.

OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Last 10 Buy Signals
Date Signal @
XRPUSDNov 28 - 13:180.911
DOGEUSDNov 28 - 13:12$0.196
XRPUSDNov 28 - 12:590.914
BTCUSDNov 28 - 12:3054 098
XRPUSDNov 28 - 12:260.920
XRPUSDNov 28 - 12:230.921
XRPUSDNov 28 - 12:190.922
BTCUSDNov 28 - 12:1654 220
XRPUSDNov 28 - 12:130.923
BTCUSDNov 28 - 12:1054 267

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.